Recruiting
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
ClinicalTrials.gov IDNCT06848946
PhasePHASE4
Enrollment132
SponsorGlaukos Corporation
Age45 Years
SexALL
Conditions studied
Glaucoma, Open-angle, Ocular Hypertension (OHT), Phacoemulsification Cataract Surgery
About this study
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
Interventions
- Combination Product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery — iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- Procedure: Sham procedure in conjunction with cataract surgery — Sham procedure in conjunction with cataract surgery
Primary outcomes
- Change from baseline in mean diurnal IOP (3 Months)
Eligibility information
Inclusion Criteria:
* Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.
* OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)
Exclusion Criteria:
* Active corneal inflammation or edema.
* Retinal disorders not associated with glaucoma.
Study locations
- Glaukos Investigator Site, Kenosha, Wisconsin 53142 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.